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This issue of the Journal contains two articles (1,2) that offer
further insight into the issues of refractoriness and tolerance in
ischemic preconditioning. Brief episodes of ischemia just be-
fore a prolonged coronary artery occlusion can markedly
reduce myocardial infarct size (3). The phenomenon of isch-
emic preconditioning has been documented in virtually every
species studied, and there is now compelling evidence for
ischemic preconditioning in humans (4). As the duration of
reperfusion between the last episode of brief ischemia and the
prolonged coronary occlusion is increased, the beneficial ef-
fects of preconditioning wane. In rats, rabbits, dogs and pigs,
separation of the brief preconditioning ischemic episodes from
the long occlusion by 60 to 120 min results in complete or
nearly complete loss of preconditioning’s powerful infarct
size-limiting effect (5–8). However if this duration is extended
to 24 to 72 h, infarct size again will be reduced (9). Hence there
is a distinct first (or classic) as well as a second (or delayed)
phase of protection.
Why the effect of ischemic preconditioning wanes after 60
to 120 min of reperfusion and reappears at 24 h is the subject
of considerable interest. It has been postulated that different
mechanisms may be involved to explain the second window
compared with the first window of protection. The first window
may involve release of adenosine during ischemic precondi-
tioning, stimulation of adenosine A1-receptors and, through G
proteins and second-messenger pathways, phosphorylation of
some unknown effector, perhaps the KATP channel. The sec-
ond window may also involve adenosine, nitric oxide, oxygen
free radicals and production of new proteins such as heat shock
protein. The exact pathways involved are complex and may
vary by species.
Our group (10) has shown that in rats, the early protective
effect that is lost after 1 to 2 h of reperfusion can be recaptured
by introducing another brief ischemic episode at the end of
60 min of reperfusion, just before a 90-min occlusion. Similar
results were reported in the rabbit (11). In these two species
the lost effects of the first window of ischemic preconditioning
could be recaptured by reawakening the memory with another
brief period of ischemia. However, studies in the pig (12)
suggested that a true refractory period exists. A second episode
of ischemic preconditioning 1 h after the first episode failed to
reduce myocardial infarct size. What is the mechanism of
refractoriness in this model? Vogt et al. (1) in this issue of the
Journal have again confirmed the fact that a second precondi-
tioning cycle at 60 min after the first is ineffective in the pig
model. They postulated that the refractory period might be due
to a reduction in intramyocardial adenosine levels, and appar-
ently they were correct. Adenosine content increased only
during the first brief preconditioning coronary occlusion but
not on sequential coronary occlusions. When an adenosine
A1-receptor agonist was infused directly into the refractory
myocardium, infarct size again was reduced. Therefore, at least
in the pig model, refractoriness appears to be related to a
decrease in endogenous adenosine and can be counteracted by
an exogenous adenosine agonist. Whether this phenomenon
holds true in other species is not clear. As previously men-
tioned, in the rat and rabbit the early phase of ischemic
preconditioning can be reinstituted by another brief period of
ischemia (10,11). It is possible that in these species the brief
episode of ischemia is again able to cause an increase in
intramyocardial adenosine levels. However, whether precondi-
tioning can be recaptured by an intramyocardial injection of an
adenosine agonist in these models remains to be determined.
Although, it is clear that adenosine plays a role in precondi-
tioning in the rabbit model, its role in the rat is controversial
(12). There are now data suggesting that adenosine may play a
role in humans. In one study (13), adenosine infusion before
percutaneous transluminal coronary angioplasty (PTCA) re-
duced ST segment elevation during balloon inflation. In an-
other study (14), pretreating patients with adenosine before
cardiopulmonary bypass was associated with improved cardiac
function and reduced use of inotropic agents. In summary, the
study by Vogt et al. (1) suggests that in the pig model,
refractoriness to the early phase of preconditioning exists, is
probably due to reduced adenosine production and can be
reversed with an adenosine A1-receptor agonist.
Recent studies from Tsuchida et al. (15) and Cohen et al.
(16) suggested that tolerance to ischemic preconditioning may
limit its potential usefulness. In a chronically instrumented
conscious rabbit model, they showed that 40 to 65 five-minute
occlusions over a period of 3 to 4 days resulted in a loss of the
benefit of ischemic preconditioning. They also showed that a
prolonged infusion of an adenosine A1-receptor agonist for 72
h resulted in a loss of protection that could not be recaptured
with a 5-min coronary occlusion. These results suggest that
there is tachyphylaxis to the benefits of preconditioning that
may be due to a desensitization of the A1-receptor on the
myocyte. Whether less frequent but repetitive occlusions could
maintain the effect of preconditioning is not known. The issue
of whether the heart can be maintained in a chronic state of
preconditioning is important from a therapeutic standpoint.
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For example, if a preconditioning mimetic drug were admin-
istered to a patient with angina, would tolerance develop
(much like what occurs with long-term nitrate therapy)?
Dana et al. (2) have addressed this issue of whether
tolerance occurs to the second window of preconditioning
when repeated doses of an adenosine A1-receptor agonist are
administered to conscious rabbits. They gave an adenosine
agonist or vehicle every 48 h five times and then 48 h later
subjected the animals to a 30-min coronary occlusion and
reperfusion. This regimen of adenosine agonist administration
was associated with a smaller infarct size than that with vehicle.
In other words, they were able to maintain these hearts in a
chronic preconditioned state. Whether this same regimen
would preserve the first window (classic preconditioning) of
protection was not studied. Obviously, the way in which the
agonist was administered (once every 48 h in this study) versus
the way in which it was administered in the study by Tsuchida
et al. (15) (continuous intravenous infusion over 72 h) may also
help explain the differences between these two studies. The
important findings of the report by Dana et al. (2) do provide
a reason to be optimistic regarding the issue of whether
pharmacologic preconditioning can result in long-term protec-
tion. A clinical implication of this study is that therapies that
simulate the second window of protection may be administered
long term and still have benefit.
However, in the present investigation by Dana et al. (2) it is
not clear whether more frequent administration of the aden-
osine agonist (for example every few hours) might have caused
tolerance to the second window of protection. There probably
is some optimal dosing regimen that affords maximal protec-
tion without the development of tolerance. A dose every 48 h
does not cause tolerance. This finding parallels to some degree
the situation of nitrate tolerance. Continuous nitrate therapy
without a nitrate-free interval is associated with rapid devel-
opment of tolerance, whereas intermittent nitrate therapy with
a nitrate-free interval is not. The same may be true for
stimulation of adenosine A1-receptors. Continuous stimulation
may result in their downregulation and desensitization,
whereas intermittent stimulation may not. If intermittent stim-
ulation is spaced appropriately, it may chronically precondition
to the second window of protection (and possibly the first
window as well, although this remains to be fully tested).
Over the past 11 years, much has been learned about the
biology of preconditioning. The two fine studies by Vogt et al.
(1) and Dana et al. (2) have extended this knowledge by
showing that refractoriness and tolerance to preconditioning
can be overcome.
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